Response to ‘Hardy–Weinberg equilibrium and control subjects’  by Lin, C.-C. et al.
Hardy–Weinberg formulation also predicts that the allelic
frequencies will remain stable from generation to gene-
ration, provided that there is no mutation, no migration,
and no natural selection in a very large population with
random mating. If the evolutionary pressures are active and/
or when the mating is not random, we can observe a
significant deviation from the expected frequencies of the
genotypes.
I read the article of Lin et al.1 with great interest and I
would like to make a few comments about it. The authors
determined a genetic polymorphism in the promoter region
of heme oxygenase-1 gene and then investigated its associa-
tion with arteriovenous fistula failure in Chinese hemodia-
lysis patients in Taiwan. They also included 286 individuals
without renal disease as control group. A dinucleotide repeat
(GT) of different length was identified in the proximal
promoter region of the human heme oxygenase-1 gene. The
authors assigned those with GT repeats X30 as allele class L
(long) and those with GT repeatso30 as allele class S (short).
Based on Table 2 of the article of Lin et al.,1 61, 163, and 62
persons showed S/S, L/S, and L/L genotypes, respectively.
There is significant deviation from Hardy–Weinberg equili-
brium (w2¼ 5.595, df¼ 1, P¼ 0.025).
Unfortunately, the authors did not mention why their
control group is not on Hardy–Weinberg equilibrium. Is
there any problem for selecting the control subjects? The
observed frequency for the heterozygote genotype was 56.9%,
whereas the expected frequency of the genotype was 49.9%.
On the other hand, both homozygote genotypes were
decreased in the control group compared to expected values.
Therefore, it is possible that the control subjects were chosen
from at least two different gene pools (or different
populations). What we can say about the patients? If they
belong to different gene pools, is there any difference(s)
between these populations for the prevalence of coronary
artery disease, cardiovascular disease, and arteriovenous
fistula failure? Finally, it seems that the reliability of the
results of Lin et al.1 dramatically decreased, and therefore
their findings must be interpreted with caution.
1. Lin CC, Yang WC, Lin SJ et al. Length polymorphism in heme oxygenase-1
is associated with arteriovenous fistula patency in hemodialysis patients.
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The authors thank Saadat1 for raising an essential issue
regarding Hardy–Weinberg equilibrium in carrying out
case–control association studies. In our paper, the main
theme was to analyze the association between HO-1 repeat
polymorphisms and arteriovenous fistula patency in
patients underwent hemodialysis. Thus, the comparisons
were mostly based on differences of genotypes between the
two case groups, that is those with and without fistula
failure. Hardy–Weinberg equilibrium was not violated in
the two case groups; therefore, the tests that we performed
were valid and so did the conclusions.
We were aware of the deviation of Hardy–Weinberg
equilibrium for the control group; therefore, the test of
association between Huntington’s disease patients and
controls was carried out by Armitage’s trend test (a valid
test even in Hardy–Weinberg disequilibrium), which was
not mentioned in our paper. To clarify further, we now add
‘using Armigates’ trend test’ in the footnote of Table 2 after
‘* signifies the P-value for the comparison between
controls and Huntington’s disease patients’.
Regarding the variation among populations, we did
genotype three informative SNP markers for Chinese sub-
populations, rs727258, rs108996795, and rs10506294, to
rule out population stratification.2 The results supported
no difference between control and the two case groups
(data not shown).
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Ultrasonography and graft
patency
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To the Editor: Robbin et al.1 have recently published an
interesting randomized study assessing the impact of
ultrasound surveillance on arteriovenous graft outcomes.
This study failed to prolong graft patency by means of
screening ultrasonography. This finding is in contradiction to
our randomized study,2 published a couple of months earlier,
where adding of ultrasound to clinical monitoring was
associated with significantly longer graft patency. A post hoc
analysis by Dossabhoy et al.3 supported our data.
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